Saffron: An Old Medicinal Plant and a Potential Novel Functional Food
María José Bagur, Gonzalo Alonso Salinas, Antonia Jiménez-Monreal et al. · Molecules · 2017 · Review
Full textCC BY
Medicine: papers
Filters2 filters applied
Status
Year
Study type
Licence
68 papers2 CorrectedQuestions on this topic
Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology
Lucie Thorel, Marion Perréard, Romane Florent et al. · Experimental & Molecular Medicine · 2024 · Review
Full textCC BY
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Enzo Alessio, Luigi Messori · Molecules · 2019 · Review
Full textCC BY
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Jake R. Conway, Eric Kofman, Shirley S. Mo et al. · Genome Medicine · 2018 · Review
Full textCC BY
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Hongshu Sui, Ningxia Ma, Ying Wang et al. · Journal of Immunology Research · 2018 · Review
Full textCC BY
Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
G Smith, R Bounds, H Wolf et al. · British Journal of Cancer · 2010
Full textCC BY
Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment
Ji Lv, Yitao Jia, Jing Li et al. · Cell Death & Disease · 2019
Full textCC BY
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Keisuke Onoi, Yusuke Chihara, Junji Uchino et al. · Journal of Clinical Medicine · 2020 · Review
Full textCC BY
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Alexandre Reuben, Christine N. Spencer, Peter A. Prieto et al. · npj Genomic Medicine · 2017
Full textCC BY
Clinical development of targeted and immune based anti-cancer therapies
N. A. Seebacher, A. E. Stacy, G. M. Porter et al. · Journal of Experimental & Clinical Cancer Research · 2019 · Review
Full textCC BY
Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling
Heike Reeh, Nadine Rudolph, Ulrike Billing et al. · Cell Communication and Signaling · 2019
Full textCC BY
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah Charych, Samira Khalili, Vidula Dixit et al. · PLOS ONE · 2017
Full textCC BY
The Role of Cancer-Associated Fibroblasts in Tumor Progression
Rushikesh S. Joshi, Samanvi S. Kanugula, Sweta Sudhir et al. · Cancers · 2021 · Review
Full textCC BY
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Minsuh Kim, Hyemin Mun, Chang Oak Sung et al. · Nature Communications · 2019
Full textCC BY
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology
Katrin P. Guillen, Maihi Fujita, Andrew J. Butterfield et al. · Nature Cancer · 2022 · Case report
Full textCC BY
STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer
Yuan-Ming Pan, Cheng-Gang Wang, Min Zhu et al. · Molecular Cancer · 2016
Full textCC BY
Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy
Shaloam Dasari, Sylvianne Njiki, Ariane Mbemi et al. · International Journal of Molecular Sciences · 2022 · Review
Full textCC BY
Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis
Taha Koray Sahin, Ruveyda Ayasun, Alessandro Rizzo et al. · Cancers · 2024 · Review
Full textCC BY
Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer
Rui Kang, Yangchun Xie, Qiuhong Zhang et al. · Cell Research · 2017
Full textCC BY
Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
Klaire Yixin Fjæstad, Anne Mette Askehøj Rømer, Victor Goitea et al. · Oncogene · 2022
Full textCC BY